Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin

被引:4
作者
Yee, Brittany E. [1 ]
Nguyen, Nghia H. [1 ]
Zhang, Bing [1 ]
Vutien, Philip [3 ]
Wong, Carrie R. [4 ]
Lutchman, Glen A. [2 ]
Nguyen, Mindie H. [2 ]
机构
[1] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[2] Stanford Univ Med Ctr, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA
[3] Rush Univ Med Ctr, Dept Internal Med, Chicago, IL USA
[4] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
关键词
genotype; 4; hepatitis C; pegylated interferon and ribavirin; sustained virologic response; SUSTAINED VIROLOGICAL RESPONSE; PEGINTERFERON PLUS RIBAVIRIN; IL28B POLYMORPHISMS PREDICT; EGYPTIAN PATIENTS; VIRUS GENOTYPE-4; ANTIVIRAL THERAPY; INITIAL TREATMENT; GENETIC-VARIATION; PEG-INTERFERON; HCV GENOTYPE-4;
D O I
10.1097/MEG.0000000000000147
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be similar to 20-70%. However, many of these studies are limited by different study designs and small sample sizes. Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN + RBV) in a systematic and quantitative manner. A comprehensive literature search in MEDLINE and EMBASE for 'genotype 4' was conducted in November 2013. Abstracts from American Association for the Study of Liver Diseases, Asian Pacific Study of the Liver, Digestive Disease Week, and European Association for the Study of the Liver in 2012/2013 were reviewed. Inclusion criteria were original studies with at least 25 treatmentnaive HCV-4 patients treated with PEG IFN+ RBV. Exclusion criteria were coinfection with HIV, hepatitis B virus, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (P < 0.05) and I-2 statistic (>50%). We included 51 studies (11 102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% [95% confidence interval (CI): 50-55%] (Q-statistic = 269.20, P < 0.05; I-2 = 81.43). On subgroup analyses, SVR was significantly associated with lower viral load, odds ratio (OR) 3.05 (CI: 1.80-5.17, P < 0.001); mild fibrosis, OR 3.17 (CI: 2.19-4.59, P < 0.001); and favorable IL28B polymorphisms, rs12979860 CC versus CT/TT, OR 4.70 (CI: 2.87-7.69, P < 0.001), and rs8099917 TT versus GT/GG, OR 5.21 (CI: 2.31-11.73, P < 0.001). HCV-4 patients treated with PEG IFN+ RBV may expect SVR rates of similar to 50%. Lower viral load, mild fibrosis, and favorable IL28B (rs12979860 CC and rs8099917 TT) are positively associated with SVR. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:1189 / 1201
页数:13
相关论文
共 115 条
[1]   HCV Infection among Saudi Population: High Prevalence of Genotype 4 and Increased Viral Clearance Rate [J].
Abdel-Moneim, Ahmed S. ;
Bamaga, Mohammad S. ;
Shehab, Gaber M. G. ;
Abu-Elsaad, Abdel-Aziz S. A. ;
Farahat, Fayssal M. .
PLOS ONE, 2012, 7 (01)
[2]   Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients [J].
Abdel-Rahman, Mahasen ;
Saad, Yasmin ;
El-Raziky, Maissa ;
Zayed, Naglaa ;
El-Akel, Wafaa ;
Said, Mohamed ;
El-Beshlawy, Mohamed ;
Esmat, Gamal .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (05) :479-484
[3]   IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection [J].
Abdo, Ayman A. ;
Al-Ahdal, Mohammed N. ;
Khalid, Saira S. ;
Helmy, Ahmed ;
Sanai, Faisal M. ;
Alswat, Khalid ;
Al-hamoudi, Waleed ;
Ali, Safiyya M. ;
Al-Ashgar, Hamad I. ;
Al-Mdani, Abdallah ;
Albenmousa, Ali ;
Al Faleh, Faleh Z. ;
Al-Anazi, Mashael ;
Khalaf, Nisreen ;
Al-Qahtani, Ahmed .
HEPATOLOGY INTERNATIONAL, 2013, 7 (02) :533-538
[4]  
Afifi MT, 2010, J GASTROEN HEPATOL, V25, pA95
[5]  
Ahmed MM, 2013, EXCLI J, V12, P605
[6]   Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital [J].
Akbar, Hisham O. ;
Al Ghamdi, Ahmad ;
Qattan, Faten ;
Fallatah, Hind I. ;
Al Rumani, Maha .
HEPATITIS MONTHLY, 2012, 12 (09)
[7]   Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents [J].
Al Ali, Jaber ;
Owayed, Salem ;
Al-Qabandi, Wafa'a ;
Husain, Khaled ;
Hasan, Fuad .
ANNALS OF HEPATOLOGY, 2010, 9 (02) :156-160
[8]   Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 [J].
Al Ashgar, Hamad ;
Helmy, Ahmed ;
Khan, Mohamed Q. ;
Al Kahtani, Khalid ;
Al Quaiz, Mohammed ;
Rezeig, Mohammed ;
Kagevi, Ingvar ;
Alshehri, Abdullah ;
Al Kalbani, Abdullah ;
Al Swat, Khalid ;
Dahab, Salim ;
Elkum, Naser ;
Al Fadda, Mohammed .
ANNALS OF SAUDI MEDICINE, 2009, 29 (01) :4-14
[9]   Hepatitis C Genotype 4: Genotypic Diversity, Epidemiological Profile, and Clinical Relevance of Subtypes in Saudi Arabia [J].
Al Ashgar, Hamad I. ;
Khan, Mohammed Q. ;
Al-Ahdal, Mohammed ;
Al Thawadi, Sahar ;
Helmy, Ahmad Salem ;
Al Qahtani, Ahmed ;
Sanai, Faisal M. .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2013, 19 (01) :28-33
[10]   Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT [J].
Al-Ali, Jaber ;
Siddique, Iqbal ;
Varghese, Rosh ;
Hasan, Fuad .
ANNALS OF HEPATOLOGY, 2012, 11 (02) :186-193